Visualization of in vivo electroporation-mediated transgene expression in experimental tumors by optical and magnetic resonance imaging

被引:0
作者
W Aung
S Hasegawa
M Koshikawa-Yano
T Obata
H Ikehira
T Furukawa
I Aoki
T Saga
机构
[1] Diagnostic Imaging Group,
[2] Molecular Imaging Center,undefined
[3] National Institute of Radiological Sciences,undefined
[4] Biophysics Group,undefined
[5] Molecular Imaging Center,undefined
[6] National Institute of Radiological Sciences,undefined
来源
Gene Therapy | 2009年 / 16卷
关键词
electroporation; transgene expression; optical imaging; magnetic resonance imaging;
D O I
暂无
中图分类号
学科分类号
摘要
In vivo electroporation (EP) is an efficient method for effective gene transfer and is highly expected for application in anticancer gene therapy. Non-invasive monitoring of gene transfer/expression is critical for optimal gene therapy. Here we report in vivo optical and high-field magnetic resonance imaging (MRI) of EP-mediated transgene expression in a tumor model. Initially, we observed spatio-temporal change in in vivo EP-mediated transgene expression by optical imaging using red fluorescence protein (RFP) as a reporter gene. Next, we constructed a dual-reporter plasmid carrying a gene-encoding MRI reporter ferritin heavy chain and RFP gene to visualize the intratumoral transgene expression by dual modality. Cells transfected with this plasmid showed lower signal intensity on in vitro T2-weighted cellular MRI and quantitatively increased the transverse relaxation rate (1/T2) compared with control cells. After conducting in vivo EP in an experimental tumor, the plasmid-injected region showed both fluorescent emissions in optical imaging and detectably lowered signal on T2-weighted MRI. The correlative immunohistological findings confirmed that both the reporter transgenes were co-expressed in this region. Thus, our strategy provides a platform for evaluating EP-mediated cancer gene therapy easily and safely without administering contrast agent or substrate.
引用
收藏
页码:830 / 839
页数:9
相关论文
共 176 条
[1]  
Alexander BL(2007)Progress and prospects: gene therapy clinical trials (part 1) Gene Therapy 14 1439-1447
[2]  
Ali RR(2007)Progress and prospects: gene therapy clinical trials (part 2) Gene Therapy 14 1555-1563
[3]  
Alton EW(2006)A look to future directions in gene therapy research for monogenic diseases PLoS Genet 2 e133-300
[4]  
Bainbridge JW(2001)Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA Exp Hematol 29 295-1605
[5]  
Braun S(2008)Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector Gene Therapy 15 1593-5903
[6]  
Cheng SH(2008)Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma J Clin Oncol 26 5896-463
[7]  
Aiuti A(2005)Cancer gene therapy using Int J Oncol 27 457-7580
[8]  
Bachoud-Levi AC(2007) electroporation of Flt3-ligand J Immunol 178 7571-759
[9]  
Blesch A(2007)Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12 Gene Therapy 14 752-571
[10]  
Brenner MK(2007) gene silencing in solid tumors by targeted electrically mediated siRNA delivery Expert Opin Drug Deliv 4 561-359